BIOCELTIX
Research BIOCELTIX (BCX.WA) on Bullrun: market cap PLN 406.62M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBCX.WA
- ExchangeXWAR
- CountryPoland
- SectorHealthcare
- IndustryBiotechnology
- CurrencyPLN
- Market capPLN 406.62M
- Financial periodQ1 2026
- RevenuePLN 0
- Net income-PLN 5.68M
- Free cash flow-PLN 7.55M
Valuation Snapshot
latest market cap is PLN 406.62M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | PLN 0 | -PLN 15.30M | -PLN 13.92M | n/a | n/a | PLN 68.40M | PLN 314.90K | PLN 73.28M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-10 | PLN 406.62M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 PLN.
About BIOCELTIX
Bioceltix S.A. engages in the development of veterinary biologics based on mesenchymal stem cells. The company's products include BCX-CM-J, a stem-cell based medicinal drug for the treatment of osteoarthritis in dogs; BCX-CM-AD, an allogeneic stem cell-based medicinal product for the treatment of atopic dermatitis in dogs; and BCX-EM, an allogeneic stem cell-based medicinal product for the treatment of osteoarthritis in horses.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is BIOCELTIX's market cap?
BIOCELTIX's market capitalization is PLN 406.62M.
What does BIOCELTIX do?
Bioceltix S.A. engages in the development of veterinary biologics based on mesenchymal stem cells. The company's products include BCX-CM-J, a stem-cell based medicinal drug for the treatment of osteoarthritis in dogs; BCX-CM-AD, an allogeneic stem cell-based medicinal product for the treatment of atopic dermatitis in dogs; and BCX-EM, an allogeneic stem cell-based medicinal product for the treatment of osteoarthritis in horses. It also develops BCX-CM-Sec, a research project aimed at developing a cell-free biological drug to treat atopic dermatitis in dogs.